2015 De Novo Classifications
This article was originally published in The Gray Sheet
A sortable and searchable table of FDA de novo classification decisions in 2015, updated monthly. Latest update: Decisions through Nov. 30.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.